Investor Relations

Overview

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

read more

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

AnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference

SAN DIEGO , March 04, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio ,

AnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates

Reported positive top-line data from an interim analysis of a Phase 2a proof-of-concept trial of etokimab in severe eosinophilic asthma Four top-line Phase 2 clinical efficacy readouts from our wholly-owned pipeline anticipated in 2019 IND filing for new wholly-owned program anticipated in second

AnaptysBio to Present at J.P. Morgan 37th Annual Healthcare Conference

SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will